Isomorphic Labs raises $5 billion Series C for AI drug discovery
Isomorphic Labs, the AI-driven drug discovery company led by Demis Hassabis, announced a $5 billion Series C funding round co-led by Greenoaks, Sequoia Capital and Andreessen Horowitz, with Alphabet also participating. The round comes months after Hassabis stepped back from his role as CEO of Google DeepMind, and follows the startup's $2.1 billion Series B raised in May.
GoKawiil's interpretation of the reporting above, not reported fact.
The massive raise reflects a broader surge of investor capital into AI-powered drug discovery, with Dealroom reporting $23.2 billion poured into the sector in 2026 alone, as rivals like OpenAI and Anthropic also push into biology-focused AI tools. Hassabis's continued leadership of Isomorphic despite leaving DeepMind suggests the drug discovery venture may now be central to his ambitions, positioning the company to compete for a leading role in AI-designed medicines heading toward clinical trials.
- Isomorphic Labs raised $5 billion in a Series C round led by Greenoaks, Sequoia, and Andreessen Horowitz, with Alphabet also investing.
- The funding follows Hassabis's departure as Google DeepMind CEO and a prior $2.1 billion Series B raised in May.
- AI drug discovery startups have attracted a record $23.2 billion in 2026, with OpenAI, Anthropic and Novo Nordisk all pursuing similar efforts.
Source: cnbc.com — Kai Nicol-Schwarz, 2026-11-17
Published there as: “Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.